Liposarcoma is the most common soft tissue sarcoma accounting for approximately 20% of all sarcomas in adults. Based on WHO criteria Liposarcomas are classified into four histological subtypes:

• Well-differentiated Liposarcoma (WDLS)
• De-differentiated Liposarcoma (DDLS)
• Myxoid/round cell Liposarcoma (M/RLS)
• Pleomorphic Liposarcoma (PMLS)

References

1. D Shibata., et al. “Is there a role for incomplete resection in the management of Retroperitoneal Liposarcoma”. Journal of the American College of Surgeons 4 (2011): 373-379.
2. Samuel Singer., et al. “Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma”. Annuals of Surgery 238 (2003): 358-371.
3. S J Neuhaus., et al. “Surgical management of primary and recurrent retroperitoneal liposarcoma”. British Journal of Surgery 92 (2005): 246-252.
4. Lucas E Matthyssens., et al. “Retroperitoneal liposarcoma: current insights in diagnosis and treatment”. Frontiers in Surgery (2015).
5. Carolin Knebel., et al. “Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years”. BMC Cancer 17 (2017): 410.
6. Xiangyu Zenga., et al. “Clinicopathological characteristics and experience in the treatment of giant retroperitoneal liposarcoma: A case report and review of the literature”. Cancer Biology and Therapy9 (2017): 660-665.
7. Alex Thomas John Lee., et al. “Clinical and Molecular Spectrum of Liposarcoma”. Journal of Clinical Oncology 36 (2017): 151-159.
8. D Ramu., et al. “Recurrent Retroperitoneal Liposarcoma: a Case Report and Literature Review”. Indian Journal of Surgical Oncology 4 (2018): 640-643.
9. Yukihiro Yokoyama., et al. “A case of retroperitoneal dedifferentiated liposarcoma successfully treated by neoadjuvant chemotherapy and subsequent surgery”. Surgical Case Reports 6 (2020): 105.

Citation

Citation: Eleni Karafoka Mavrou. “Retroperitoneal Liposarcoma: The Endless Challenge". Acta Scientific Clinical Case Reports 2.1 (2021): 24-25.

Copyright

Copyright: © 2021 Eleni Karafoka Mavrou. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.